EFPIA：2025年在欧盟《药品通用立法》中加强新型抗菌药物的激励措施报告（英文版）

Given the growing threat of antimicrobial resistance (AMR) and the broken antimicrobial pipeline1 , Europe urgently needs to introduce predictable and meaningfully sized pull incentives to stimulate the research and development (R&D) of novel antimicrobials. Recognising this, the European Commission put forward pull incentive provisions in its 2023 proposal for a Pharmaceutical Regulation. Chapter III introduced the Transferable Exclusivity Voucher (TEV), which has since been examined extensivel